AstraZeneca and Johnson & Johnson to continue COVID-19 vaccine trials in the US

AstraZeneca and Johnson & Johnson to continue COVID-19 vaccine trials in the US

Two of the frontrunners in finding a viable medicine against COVID-19 are now able to resume their tests.

The week started with promising news from two of the companies that are working on a potential COVID-19 vaccine.

AstraZeneca and Johnson & Johnson announced that they are ready to resume the temporarily paused vaccine trials. The decision to halt the trails came after each of them reported that a volunteer got unexpectedly sick.

AstraZeneca was authorized by the US Food and Drug Administration to restart the trials after an inquiry showed that the global safety data showed that it's all safe. AstraZeneca's trial was held in September in the UK after a person developed a neurological condition.

Johnson & Johnson's trial was paused earlier this October after a participant reported an "unexpected illness." At the end of last week, JnJ stated that "no clear cause" led to the illness and that "preparations to resume the trial in the United States are now underway." No clear date was specified when the trial will resume, but according to people familiar with the matter, the event will probably occur next week.

According to government health officials and independent experts, these temporary pauses are setting an example of how safety processes work.

Following the news, AstraZeneca opened 0.87% higher, while Johnson & Johnson is at -0.03%.

Read more about JnJ's situation here!

Sources: edition.cnn.com, finance.yahoo.com

La información presentada aquí está preparada por CAPEX.com y no pretende constituir un asesoramiento de inversión. La información aquí se proporciona como una comunicación general de marketing con propósitos solo de información, y como tal, no se han preparado de acuerdo con los requisitos legales diseñados para promover la independencia de un estudio de inversión, y no está sujeto a ninguna prohibición para hacer frente con antelación a la diseminación de los análisis de inversión.

Los usuarios / lectores no deben confiar únicamente en la información presentada aquí y deben hacer su propia investigación / análisis leyendo también la investigación subyacente real. El contenido adjunto es genérico y no tiene en cuenta las circunstancias personales, la experiencia de inversión o la situación financiera actual.

Por lo tanto, Key Way Investments Ltd no aceptará ninguna responsabilidad por las pérdidas de los comerciantes debido al uso y el contenido de la información presentada en este documento. El rendimiento pasado no es un indicador confiable de resultados futuros.